# Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients

> **NCT05147090** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **The University of Hong Kong** · enrollment: 106 (estimated)

## Conditions studied

- Chronic Hepatitis b
- NAFLD
- Cirrhosis
- Fibrosis, Liver
- Empagliflozin
- SGLT2 Inhibitors

## Interventions

- **DRUG:** Empagliflozin 10 MG
- **DRUG:** Placebo pills

## Key facts

- **NCT ID:** NCT05147090
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-02
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 106 (ESTIMATED)
- **Last updated:** 2026-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05147090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05147090, "Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05147090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*